Skip to main content

Table 2 Characteristics of subjects stratified by percentage of eosinophils and neutrophils in sputum

From: CXC chemokine superfamily induced by Interferon-γ in asthma: a cross-sectional observational study

  Paucigranulocytic Eosinophil-predominant or Neutrophil-predominant Mixed granulocytic Healthy Subjects Overall
P value*
Subjects, n (%) 9 (23) 22 (56) 8 (21) 12  
 Eos dominant/Neu dominant, n (%) N. A. 19/3 (86/14) N. A. N. A.  
Age, y 50 (20–71) 58 (30–71) 55 (22–72) 47 (30–57) N. S.
Male/female, n (Male, %) 3 (33)/6 9 (41)/13 4 (50)/4 4 (33)/8 N. S.
BMI 24.5 (6.1) 21.8 (2.5) 21.9 (1.0) 22.1 (3.1) N. S.
Duration of asthma (y) 5.1 (5.6) 10.8 (9.7) 23.4 (20.5)† N. A. 0.01
Ex-smokers, n (%) 4 (44) 9 (41) 1 (12) 0 (0) 0.03
Non-severe/Severe, n (Severe, %) 6/1 (11) 14/8 (36) 6/2 (25) N. A. N. S.
Medication
ICS dose (μg/day) 900 (500–1150) 800 (400–1150) 800 (400–1200) N. A. N. S.
 LABA, n (%) 6 (67) 12 (55) 7 (88) N. A. N. S.
 LTRA/TP, n (%) 6 (67)/3 (33) 13 (59)/11 (50) 7 (88)/4 (50) N. A. N. S.
 Oral corticosteroids, n (%) 0 (0) 4 (18) 1 (13) N. A. N. S.
Atopy, n (%) 5 (57) 14 (64) 6 (75) 5 (42) N. S.
Asthma control and health care use, past year
 β-agonist use/day 0.00 (0.00–0.01) 0.00 (0.00–0.02) 0.00 (0.00–0.68) N. A. N. S.
 Oral Corticosteroid bursts 1.0 (1.0–2.5) 1.0 (0.0–1.0) 1.0 (0.0–2.0) N. A. N. S.
FEV1, L/min 2.3 (0.6) 2.1 (0.9)‡ 2.0 (1.0)§ 3.2 (0.8) 0.05
FEV1, % predicted 89.7 (14.9) 81.3 (22.4)װ 72.9 (18.2)¶ 105.5 (14.6) 0.01
FeNO, ppb 18.5 (12.3–45.5) 34.5 (13.3–51.0) 53.2 (21.5–99.0) N.D. N. S.
  1. Data are presented as means (SD) unless otherwise indicated. Nonparametric data are shown as medians (25 to 75 %). Age is shown as mean (minimum to maximum)
  2. ICS = inhalation corticosteroid (beclomethasone), where 1 μg beclomethasone = 1 μg budesonide = 0.5 μg fluticasone
  3. *P values are calculated with the use of the Kruskal-Wallis test and the Mann–Whitney U test for nonparametric data, ANOVA for variables with a parametric distribution, and Fisher’s exact test for comparison of proportions. Initial analyses with a significant difference are further explored by post hoc pairwise analyses (Bonferroni correction)
  4. LABA, Long acting β2-agonist; LTRA, Leukotriene receptor antagonist; Eos, eosinophil, Neu, neutrophil
  5. vs. Paucigranulocytic, † p = 0.01
  6. vs. Healthy, ‡ p = 0.006; § p = 0.02; װ p = 0.004; ¶ p = 0.002
  7. N. A.; not applicable. N.D.: not done